Prevention of Asthma Relapse After Discharge From Emergency - Full Text View

Prevention of Asthma Relapse After Discharge From Emergency (PARADE)

This study has been completed.

First Received: May 12, 2006 Last Updated: March 25, 2009 History of Changes

Sponsor:	AstraZeneca
Information provided by:	AstraZeneca
ClinicalTrials.gov Identifier:	NCT00326053

Purpose

The purpose of this study is to compare the Symbicort® Turbuhaler® to both Pulmicort® Turbuhaler® and Bricanyl® Turbuhaler® for the treatment of asthma after discharge from the emergency room

Condition	Intervention	Phase
Asthma	Drug: Budesonide/formoterol	Phase III

Study Type:	Interventional
Study Design:	Allocation: Randomized Control: Active Control Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double-Blind Primary Purpose: Treatment
Official Title:	A Comparison of Budesonide/Formoterol Turbuhaler® 160/4.5 µg 2 Inhalations BID Plus as Needed to Budesonide Turbuhaler® 320 µg 2 Inhalations BID Plus Terbutaline Turbuhaler® 0.4 mg as Needed for the Prevention of Asthma Relapse

Resource links provided by NLM:

MedlinePlus related topics: Asthma

Drug Information available for: Formoterol fumarate Budesonide Arformoterol Formoterol Arformoterol Tartrate

U.S. FDA Resources

Further study details as provided by AstraZeneca:

Primary Outcome Measures:

Time to first asthma relapse

Secondary Outcome Measures:

Mean use of reliever medication
Asthma Control Questionnaire (ACQ) score
Complete AE and SAE collection

Estimated Enrollment:	600
Study Start Date:	May 2006
Study Completion Date:	May 2007

Eligibility

Ages Eligible for Study:	18 Years to 65 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

18 - 65 years of age
Presenting at a study emergency department with an asthma exacerbation

Exclusion Criteria:

Admission to hospital
Patients receiving more than 2000 µg/day of beclomethasone equivalent inhaled corticosteroids (1000 µg/day fluticasone or 1600 µg/day budesonide)

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00326053

Locations

Canada
Research Site
Quebec, Canada
Canada, Alberta
Research Site
Calgary, Alberta, Canada
Research Site
Edmonton, Alberta, Canada
Research Site
Lethbridge, Alberta, Canada
Research Site
St. Albert, Alberta, Canada
Canada, British Columbia
Research Site
Vancouver, British Columbia, Canada
Research Site
Nanaimo, British Columbia, Canada
Canada, Nova Scotia
Research Site
Halifax, Nova Scotia, Canada
Research Site
Truro, Nova Scotia, Canada
Canada, Ontario
Research Site
Kingston, Ontario, Canada
Research Site
Toronto, Ontario, Canada
Research Site
Ottawa, Ontario, Canada
Research Site
Thunder Bay, Ontario, Canada
Research Site
Hamilton, Ontario, Canada
Research Site
Niagara Falls, Ontario, Canada
Canada, Prince Edward Island
Research Site
Charlottetown, Prince Edward Island, Canada
Canada, Quebec
Research Site
La Malbaie, Quebec, Canada
Research Site
Montreal, Quebec, Canada
Research Site
Ste-Foy, Quebec, Canada
Canada, Saskatchewan
Research Site
Saskatoon, Saskatchewan, Canada

Sponsors and Collaborators

AstraZeneca

Investigators

Study Director:	Gloria Jordana, MD	AstraZeneca
Principal Investigator:	Brian Rowe, MD	University of Alberta

More Information

No publications provided

Study ID Numbers:	D5890L00017, PARADE
Study First Received:	May 12, 2006
Last Updated:	March 25, 2009
ClinicalTrials.gov Identifier:	NCT00326053 History of Changes
Health Authority:	Canada: Health Canada

Keywords provided by AstraZeneca:

Asthma Reoccurrence
Acute Asthma
Patient Discharge

Emergency Service, Hospital
Asthma Exacerbation
Asthma Relapse

Additional relevant MeSH terms:

Anti-Inflammatory Agents
Respiratory System Agents
Neurotransmitter Agents
Disease Attributes
Molecular Mechanisms of Pharmacological Action
Adrenergic Agents
Bronchial Diseases
Symbicort
Physiological Effects of Drugs
Hormones, Hormone Substitutes, and Hormone Antagonists
Hormones
Adrenergic Agonists
Hypersensitivity
Lung Diseases, Obstructive
Pathologic Processes

Respiratory Tract Diseases
Therapeutic Uses
Formoterol
Adrenergic beta-Agonists
Immune System Diseases
Budesonide
Asthma
Anti-Asthmatic Agents
Glucocorticoids
Recurrence
Pharmacologic Actions
Autonomic Agents
Lung Diseases
Hypersensitivity, Immediate
Peripheral Nervous System Agents

ClinicalTrials.gov processed this record on March 18, 2010